Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 16Leukemia, Myelomonocytic, Acute 11Leukemia, Monocytic, Acute 11Leukemia, Megakaryoblastic, Acute 11Leukemia, Erythroblastic, Acute 11Breast Neoplasms 9Congenital Abnormalities 8Glioblastoma 7Pancreatic Neoplasms 6Recurrence 5Leukemia, Myelomonocytic, Chronic 5Leukemia, Eosinophilic, Acute 5Leukemia, Basophilic, Acute 5Leukemia 5Gliosarcoma 5Anemia, Refractory, with Excess of Blasts 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Carcinoma, Non-Small-Cell Lung 4Brain Neoplasms 4Blast Crisis 4Urinary Bladder Neoplasms 3Unspecified Adult Solid Tumor, Protocol Specific 3Squamous Cell Carcinoma of Head and Neck 3Multiple Myeloma 3Lung Neoplasms 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Inflammatory Breast Neoplasms 3Head and Neck Neoplasms 3Breast Neoplasms, Male 3Thyroid Neoplasms 2

Interventions

veliparib 1tipifarnib 1Mitozytrex 1Mitomycin 1Immunoglobulin G 1Exercise 1Erlotinib Hydrochloride 1Disulfides 1Bevacizumab 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Solid Neoplasm × tipifarnib × Clear all
NCT00085553 2018-05-18

Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
29 enrolled

Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡